Switch to:
Also traded in: Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 9.57
ARNA's Cash-to-Debt is ranked lower than
57% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ARNA: 9.57 )
Ranked among companies with meaningful Cash-to-Debt only.
ARNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.46  Med: 4 Max: 11204.39
Current: 9.57
0.46
11204.39
Equity-to-Asset 0.87
ARNA's Equity-to-Asset is ranked higher than
83% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARNA: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
ARNA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.53 Max: 0.98
Current: 0.87
0.02
0.98
Debt-to-Equity 0.11
ARNA's Debt-to-Equity is ranked higher than
71% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. ARNA: 0.11 )
Ranked among companies with meaningful Debt-to-Equity only.
ARNA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.59 Max: 19.85
Current: 0.11
0
19.85
Debt-to-EBITDA -0.58
ARNA's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. ARNA: -0.58 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ARNA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -82.2  Med: -1.12 Max: -0.32
Current: -0.58
-82.2
-0.32
Piotroski F-Score: 3
Altman Z-Score: 13.06
Beneish M-Score: -2.93
WACC vs ROIC
15.06%
-605.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -462.86
ARNA's Operating Margin % is ranked lower than
72% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. ARNA: -462.86 )
Ranked among companies with meaningful Operating Margin % only.
ARNA' s Operating Margin % Range Over the Past 10 Years
Min: -2405.23  Med: -477.45 Max: 0.92
Current: -462.86
-2405.23
0.92
Net Margin % -452.86
ARNA's Net Margin % is ranked lower than
74% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. ARNA: -452.86 )
Ranked among companies with meaningful Net Margin % only.
ARNA' s Net Margin % Range Over the Past 10 Years
Min: -2421.99  Med: -589.01 Max: -23.88
Current: -452.86
-2421.99
-23.88
ROE % -26.62
ARNA's ROE % is ranked higher than
55% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ARNA: -26.62 )
Ranked among companies with meaningful ROE % only.
ARNA' s ROE % Range Over the Past 10 Years
Min: -246.16  Med: -132.46 Max: -20.4
Current: -26.62
-246.16
-20.4
ROA % -21.33
ARNA's ROA % is ranked higher than
58% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ARNA: -21.33 )
Ranked among companies with meaningful ROA % only.
ARNA' s ROA % Range Over the Past 10 Years
Min: -65.19  Med: -40.69 Max: -6.47
Current: -21.33
-65.19
-6.47
ROC (Joel Greenblatt) % -339.64
ARNA's ROC (Joel Greenblatt) % is ranked higher than
57% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ARNA: -339.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARNA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -339.64  Med: -109.69 Max: -10.83
Current: -339.64
-339.64
-10.83
3-Year Revenue Growth Rate -27.30
ARNA's 3-Year Revenue Growth Rate is ranked lower than
73% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARNA: -27.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARNA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.6 Max: 35
Current: -27.3
0
35
3-Year EBITDA Growth Rate -8.60
ARNA's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. ARNA: -8.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARNA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -74.3  Med: 7.6 Max: 70.7
Current: -8.6
-74.3
70.7
3-Year EPS without NRI Growth Rate -0.80
ARNA's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ARNA: -0.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARNA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -104.7  Med: 15.1 Max: 57.1
Current: -0.8
-104.7
57.1
GuruFocus has detected 3 Warning Signs with Arena Pharmaceuticals Inc ARNA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARNA's 30-Y Financials

Financials (Next Earnings Date: 2019-03-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ARNA Guru Trades in

Q1 2018

ARNA Guru Trades in Q1 2018

Joel Greenblatt 5,406 sh (New)
Leon Cooperman 34,000 sh (New)
Steven Cohen 337,400 sh (+101.79%)
Jim Simons 235,550 sh (-58.36%)
» More
Q2 2018

ARNA Guru Trades in Q2 2018

Steven Cohen 1,367,400 sh (+305.28%)
Joel Greenblatt Sold Out
Leon Cooperman Sold Out
Jim Simons Sold Out
» More
Q3 2018

ARNA Guru Trades in Q3 2018

PRIMECAP Management 988,399 sh (New)
Murray Stahl 4,500 sh (New)
Steven Cohen 956,900 sh (-30.02%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ARNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CORT, SZSE:002030, NAS:ESPR, NAS:INSM, NAS:ACAD, NAS:ICPT, BOM:539268, XMCE:ALM, NYSE:CBM, NAS:AIMT, SZSE:002287, NAS:GBT, NAS:ENTA, HKSE:06826, NAS:MYOK, XKRX:095700, NAS:DNLI, LSE:GNS, NAS:XLRN, SZSE:002653 » details
Traded in other countries:RN3N.Germany, 0S54.UK,
Headquarter Location:USA
Arena Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Top Ranked Articles about Arena Pharmaceuticals Inc

Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis
Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 10
Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors
Arena Pharmaceuticals Expands Senior Management Team to Support Commercialization and Medical Affairs
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
Arena Pharmaceuticals Presented Preclinical Data for APD418 in Development for Treatment of Decompensated Heart Failure at American Heart Association Scientific Sessions
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2018 Financial Results
Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7
Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting

Ratios

vs
industry
vs
history
PB Ratio 4.01
ARNA's PB Ratio is ranked higher than
58% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ARNA: 4.01 )
Ranked among companies with meaningful PB Ratio only.
ARNA' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 7.8 Max: 135.77
Current: 4.01
1.23
135.77
PS Ratio 57.79
ARNA's PS Ratio is ranked lower than
85% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARNA: 57.79 )
Ranked among companies with meaningful PS Ratio only.
ARNA' s PS Ratio Range Over the Past 10 Years
Min: 3.44  Med: 26.22 Max: 85.95
Current: 57.79
3.44
85.95
EV-to-EBIT -15.42
ARNA's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ARNA: -15.42 )
Ranked among companies with meaningful EV-to-EBIT only.
ARNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -187.7  Med: -7.45 Max: -0.7
Current: -15.42
-187.7
-0.7
EV-to-EBITDA -16.01
ARNA's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ARNA: -16.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARNA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -350.4  Med: -4.7 Max: 722.4
Current: -16.01
-350.4
722.4
EV-to-Revenue 66.03
ARNA's EV-to-Revenue is ranked lower than
79% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. ARNA: 66.03 )
Ranked among companies with meaningful EV-to-Revenue only.
ARNA' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.3  Med: 23.3 Max: 95
Current: 66.03
3.3
95
Current Ratio 26.08
ARNA's Current Ratio is ranked higher than
96% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ARNA: 26.08 )
Ranked among companies with meaningful Current Ratio only.
ARNA' s Current Ratio Range Over the Past 10 Years
Min: 1.68  Med: 6.58 Max: 91.72
Current: 26.08
1.68
91.72
Quick Ratio 26.08
ARNA's Quick Ratio is ranked higher than
96% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ARNA: 26.08 )
Ranked among companies with meaningful Quick Ratio only.
ARNA' s Quick Ratio Range Over the Past 10 Years
Min: 1.68  Med: 6.58 Max: 91.72
Current: 26.08
1.68
91.72
Days Inventory 230.71
ARNA's Days Inventory is ranked lower than
83% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. ARNA: 230.71 )
Ranked among companies with meaningful Days Inventory only.
ARNA' s Days Inventory Range Over the Past 10 Years
Min: 113.04  Med: 301.17 Max: 555.68
Current: 230.71
113.04
555.68
Days Sales Outstanding 19.65
ARNA's Days Sales Outstanding is ranked higher than
54% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. ARNA: 19.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARNA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.27  Med: 48.63 Max: 134.42
Current: 19.65
2.27
134.42
Days Payable 89.67
ARNA's Days Payable is ranked higher than
55% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. ARNA: 89.67 )
Ranked among companies with meaningful Days Payable only.
ARNA' s Days Payable Range Over the Past 10 Years
Min: 30.81  Med: 120.14 Max: 386.18
Current: 89.67
30.81
386.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.30
ARNA's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. ARNA: -21.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARNA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -205.3  Med: -21.3 Max: 1.2
Current: -21.3
-205.3
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.42
ARNA's Price-to-Net-Cash is ranked higher than
74% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. ARNA: 4.42 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ARNA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.82  Med: 3.17 Max: 136.56
Current: 4.42
0.82
136.56
Price-to-Net-Current-Asset-Value 4.32
ARNA's Price-to-Net-Current-Asset-Value is ranked higher than
73% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. ARNA: 4.32 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARNA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.78  Med: 3.35 Max: 1462.5
Current: 4.32
0.78
1462.5
Price-to-Tangible-Book 4.01
ARNA's Price-to-Tangible-Book is ranked higher than
66% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ARNA: 4.01 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARNA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.62  Med: 3.31 Max: 70.08
Current: 4.01
0.62
70.08
Price-to-Median-PS-Value 2.20
ARNA's Price-to-Median-PS-Value is ranked lower than
92% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ARNA: 2.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARNA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.81 Max: 5.9
Current: 2.2
0.14
5.9
Earnings Yield (Greenblatt) % -6.49
ARNA's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ARNA: -6.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARNA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -149.2  Med: -13.4 Max: -0.5
Current: -6.49
-149.2
-0.5

More Statistics

Revenue (TTM) (Mil) $24.69
EPS (TTM) $ -2.68
Beta2.08
Volatility41.14%
52-Week Range $30.00 - 50.05
Shares Outstanding (Mil)49.41

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 13 13 14
EBIT (Mil $) -144 -132 -146
EBITDA (Mil $) -140 -125 -140
EPS ($) -3.03 -2.27 -2.57
EPS without NRI ($) -3.03 -2.27 -2.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}